Keeping Track: US FDA Approvals For Tibsovo, Kisqali And Second Neupogen Biosimilar
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: A Week Of Calm As Shutdown Drags On
The latest drug development news and highlights from our US FDA Performance Tracker.
2018 Complete Response Letters: Efficacy Issues Drove Most Product Rejections
US FDA issued at least seven rejections to novel products; opioid analgesic sponsors had very little success, while biosimilar developers had a so-so year.